{"groups":[{"description":"Patients receive PI3K-beta inhibitor GSK2636771 400 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nPI3K-beta Inhibitor GSK2636771: Given PO","id":"FG000","title":"Treatment (GSK2636771)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"25"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"comment":"Primary efficacy analysis set","type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients who had tumor with complete loss of cytoplasmic and nuclear staining for PTEN with IHC were assigned to sub-protocol P. The mutation status was determined by MATCH central Oncomine assay for all patients in this arm.","recruitmentDetails":"Subprotocol P was activated on February 25, 2016. Thirty-five patients were enrolled on EAY131-P between March 21, 2016, and February 17, 2017. All patients were enrolled on the basis of the results from the NCI-MATCH assay."}